Literature DB >> 371802

Combined DTIC and cis-dichlorodiammineplatinum(II) therapy for patients with disseminated melanoma: a Northern California Oncology Group study.

M A Friedman, D A Kaufman, J E Williams, K J Resser, E H Rosenbaum, R J Cohen, A B Glassberg, M R Blume, J Gershow, E Y Chan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 371802

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  5 in total

1.  Combination chemotherapy of dacarbazine and fotemustine in disseminated malignant melanoma. Experience of the French Study Group.

Authors:  M F Avril; J Bonneterre; M Delaunay; E Grosshans; P Fumoleua; L Israel; R Bugat; M Namer; D Cupissol; P Kerbrat
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  A phase II study of the efficacy of diamminedichloroplatinum (cisplatin) for the control of locally recurrent and intransit malignant melanoma of the extremities using tourniquet outflow-occlusion techniques.

Authors:  K I Bland; A K Kimura; D E Brenner; M A Basinger; M Hirsch; I F Hawkins; K K Pierson; E M Copeland
Journal:  Ann Surg       Date:  1989-01       Impact factor: 12.969

Review 3.  Systemic chemotherapy for malignant melanoma.

Authors:  A S Coates
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

4.  Combination chemotherapy with ifosfamide and cis-dichlorodiammineplatinum (II) in advanced malignant melanoma.

Authors:  R Becher; S Seeber; C G Schmidt
Journal:  J Cancer Res Clin Oncol       Date:  1980       Impact factor: 4.553

5.  Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin.

Authors:  D Pectasides; H Yianniotis; N Alevizakos; D Bafaloukos; V Barbounis; J Varthalitis; M Dimitriadis; A Athanassiou
Journal:  Br J Cancer       Date:  1989-10       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.